

**PATENT** 

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Iversen et al.

SERIAL NO.: 09/493,427

FILED: January 20, 2000

FOR: ANTISENSE RESTENOSIS COMPOSITION AND METHOD

EXAMINER: Epps-Ford, J.

ART UNIT: 1633

CONF. No. 2225

## <u>Supplemental Information Disclosure Statement Within Three Months of</u> <u>Application Filing or Before First Action – 37 CFR 1.97(b)(4)</u>

Mail Stop RCE Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

## 1. <u>Timing of Submission</u>

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits after the filing of a request for continued examination under 37 CFR §1.114, whichever occurs last [37 CFR 1.97(b)(4)]. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

### 2. Cited Information

The following:

	⊠ ⊠	Copies of the following references are enclosed: All cited references except copies of U.S. patents and published applications (See C.F.R. § 1.98(a)(2)(i)).					
3.	□ No.	Copies of the following references can be found in parent Application					
	110.	<ul><li>☐ All cited references</li><li>☐ References marked by asterisks</li></ul>					

The following references are not in English. For each such reference, the undersigned has enclosed (i) a translation of the reference; (ii) a copy of a communication from a foreign patent office or International Searching

	English-language counterpart, or (in reference prepared by a third part translation, English-language counterpart)		
4.	Effect of Information Disclosure Statement (2) This Information Disclosure Statement is no (i) a search has been made; (ii) additional in this application does not exist; (iii) the information does not exist.	t to be construed as a representation that: aformation material to the examination of formation, protocols, results and the like bling; or (iv) the cited information is, or is In addition, applicant does not admit that es prior art to the subject invention and	
5.	Fee Payment No fees are believed due. However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.		
6.	Patent Term Adjustment (37 CFR 1.704(d))  The undersigned states that each item of in a communication from a foreign patent of this communication was not received by § 1.56(c) more than thirty days prior to the 1.704(d).	ffice in a counterpart application and that any individual designated in 37 C.F.R.	
		Respectfully submitted,	
Date:_	1-20-2006	Leelma Jorthee LeeAnn Gorthey	
Corres	enondence Address	Registration No. 37,337	

Correspondence Address: Customer No. 22918

Tel: 650 838-4403

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Form PTO-1449 (Modified) / (Use several sheets if necessary) JAN 2 0 2006

COMPLETE IF KNOWN				
Application Number	09/493,427			
Confirmation Number	2225			
Filing Date	January 29, 2000			
Airst Named Inventor	Iversen et al.			
Group Art Unit	1633			
Examiner Name	Epps-Ford, J.			
Attorney Docket No.	50450-8025 LIS00			

Sheet 1 of 2 1

Silee	il [	<u> </u>	<u>l</u>	01 /8	Attorney Docket No.	1 50450-8025.050	<u> </u>	
			<del> </del>	I	J.S. PATENT DOCUMENTS		· · · · · · · · · · · · · · · · · · ·	
Examiner Initials	Cite No.	U.	S. Patent or Applic	· · · · · · · · · · · · · · · · · · ·	Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	5,
					······································			
*								
<del> </del>	1	l		FOF	REIGN PATENT DOCUMENTS	-1	<del></del>	
Examiner Initial	Cite No.	For Office	eign Patent or App	lication  Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	Т
		000		(			J.,,,,,,	
	<u> </u>	<u> </u>	OTHER P	RIOR AR	' Г-NON PATENT LITERATURE I	DOCUMENTS	<u> </u>	_
Examiner Initials	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city				Т			
		Kutryk, M. et al., "Local Intracoronary Administration of Antisense Oligonucleotide Against c-myc for the Prevention of In-Stent Restenosis", Journal of the American College of Cardiology 39(2):281-287, 2002.						
		Bult, Hidde, "Restenosis: a challenge for pharmacology", <i>TiPS</i> <b>21</b> :274-279, 2000.						
		Kent, K. and Liu, B., "Intimal Hyperplasia – Still Here after All These Years!", Annals of Vascular Surgery, Inc. 18(2):135-137, 2004.						
		Roqué, F. et al., "Safety of Intracoronary Administration of c-myc Antisense Oligomers After Percutaneous Transluminal Coronary Angioplasty (PTCA)", Antisense & Nucleic Acid Drug Development 11:99-106, 2001.						
		Gruberg, L. et al., "Novel approaches for the prevention of restenosis", Exp. Opin. Invest.  Drugs 9(11):2555-2578, 2000.						

EXAMINER		DATE CONSIDERED		
	•			
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not			
	considered. Include copy of this form with next communication to application(s).			